Ra Medical Systems Stock

Ra Medical Systems AAQS

Delisted

The The AAQS of Ra Medical Systems (RMED) as of Aug 22, 2026 is 1. In the previous year, The AAQS was 1.00 — a change of 0.00% (lower).

AAQS

1

YoY

0.00%

Last updated:

Ra Medical Systems has a current AAQS of 1.

A high AAQS can be seen as a positive indicator that the company is developing successfully.

Investors can assume that the company is on a good path to generate profits.

On the other hand, it is important to consider the AAQS of the stock Ra Medical Systems in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.

In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.
Access this data via the Eulerpool API

Ra Medical Systems Stock analysis

What does Ra Medical Systems do? Ra Medical Systems Inc. is a California-based company specializing in the development and sale of medical devices for the treatment of vascular diseases. The company was founded in 2002 and is headquartered in Carlsbad. The company was founded by Dr. Dean Irwin and Dr. Melissa Burstein, both experts in laser therapy. The company initially focused on developing laser systems for the treatment of skin diseases. In 2016, the company changed its business strategy and shifted its focus to the development of medical devices for the treatment of vascular diseases. Since then, the company has become a leading provider of devices for the treatment of peripheral artery occlusive disease (PAOD) and other vascular diseases. The business model of Ra Medical Systems Inc. is based on selling high-tech medical devices and their corresponding accessories. The company sells its products directly to medical facilities and healthcare providers in the US and some international markets. The company also provides training, technical support, and service to ensure the safe and effective use of its products. Ra Medical Systems Inc. offers two main products: the DABRA™ System and the Pharos™ System. Both systems use pulsed laser therapy for the treatment of vascular diseases. The DABRA™ System is a laser system specifically designed for the treatment of peripheral artery occlusive disease (PAOD). It is the only FDA-approved system that offers atherectomy laser therapy. The system enables fast and safe treatment of blocked arteries and is less invasive than traditional surgical procedures. The DABRA™ System also has the potential to reduce the need for long-term medication and repeated procedures, which can lower treatment costs. The Pharos™ System is a laser system specifically designed for the treatment of skin diseases such as psoriasis, vitiligo, and atopic dermatitis. The system uses a high-energy dose to selectively destroy abnormal functioning tissue without affecting surrounding tissue. The Pharos™ System has the potential to improve the quality of life for patients with skin diseases and expand therapeutic options for this patient group. Ra Medical Systems Inc. also offers a complete accessory catalog for its products, including catheters and accessories for the DABRA™ System and handpieces and cooling devices for the Pharos™ System. In conclusion, Ra Medical Systems Inc. is a leading provider of medical devices for the treatment of vascular diseases and skin diseases. The company specializes in the development of high-tech laser systems that provide safe and effective procedures for patients and doctors. The DABRA™ System is a revolutionary laser system for the treatment of PAOD that has the potential to reduce the need for invasive surgical procedures and long-term medication. The Pharos™ System expands therapeutic options for patients with skin diseases and has the potential to improve the quality of life for this patient group. Ra Medical Systems is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ra Medical Systems stock

The AAQS of Ra Medical Systems is 1 in 2026.

On Eulerpool you can find the complete historical development of The AAQS Ra Medical Systems since 2006 – with annual values, charts, and detailed analysis.

The AAQS is a key figure developed by AlleAktien.

The AAQS is a key figure developed by AlleAktien.

Access this data via the Eulerpool API

Quality — Ra Medical Systems

All Key Metrics — Ra Medical Systems